Inventaire - your friends and communities are your best library

Pharmacogenetics of lipid diseases

Published in: Human genomics

Date of publication: January 1, 2004

Main subject: arteriosclerosis, hyperlipidemia, pharmacogenetics, lipid, apolipoproteins E

Bibliographic databases:

Cites articles 102

Date

Title

Authors

August 1, 1975

Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (APO E-III) in the very-low-density lipoproteins
August 1, 1987

Apolipoprotein E polymorphism and plasma cholesterol response to probucol
February 1, 1990

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
July 1, 1990

Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
November 1, 1991

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
April 1, 1993

Phenotyping. On reaching base camp (1950-1975)
January 1, 1993

Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia
February 1, 1993

Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy

, , , ,
April 1, 1993

Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients
July 1, 1993

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
March 1, 1995

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

,
December 1, 1995

Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?
November 1, 1997

Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients
January 1, 1997

Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients,Influence of Apolipoprotein E Polymorphism on Bezafibrate Treatment Response in Dyslipidemic Patient
August 1, 1998

Genotype/phenotype correlations in familial hypercholesterolaemia
June 1, 1998

Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia
February 1, 1998

Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations
February 1, 1998

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group
July 1, 1998

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia
January 1, 1998

The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group

,
January 1, 1998

The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group
January 1, 1998

Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group
August 1, 1998

Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy
November 1, 1998

Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol
October 26, 1999

Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred

,
October 1, 1999

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
August 1999

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
August 1999

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
August 1999

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
June 1, 1999

Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study
February 1, 1999

The genetics of serum lipid responsiveness to dietary interventions
March 1999

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia

,

Article -

Welcome to inventaire

The library of your friends and communities

You are offline